SLK Antibody

What is SLK and what cellular functions does it regulate?

SLK (also known as KIAA0204 and STK2) belongs to the protein kinase superfamily, specifically the STE Ser/Thr protein kinase family and STE20 subfamily. It plays significant roles in:

• Cell proliferation and cytoskeletal remodeling

• Embryonic development (essential for viability)

• Podocyte integrity in kidney function

• Apoptosis and actin stress fiber dissolution

• Focal adhesion turnover through Paxillin phosphorylation

• Myoblast fusion during development

SLK is expressed mainly in podocytes, although minor expression has been detected in mesangial and endothelial cells. In kidney studies, colocalization analysis showed the Pearson correlation coefficient between SLK and synaptopodin (podocyte marker) was 0.27 ± 0.01, while correlation with PECAM (endothelial marker) was much lower at 0.07 ± 0.02 .

What are the standard molecular weights for SLK detection in Western blot analysis?

SLK typically appears at two distinct molecular weights in Western blot analysis:

When selecting antibodies, verify which form(s) the antibody can detect. Some antibodies might preferentially recognize one form over the other .

What applications are most commonly supported by commercial SLK antibodies?

Most commercially available SLK antibodies support multiple applications:

Always validate the antibody for your specific application and cell/tissue type before proceeding with experiments .

How can I properly validate the specificity of an SLK antibody?

A robust validation strategy should include:

• Knockout/knockdown comparison: Compare signal between wild-type and SLK knockout or knockdown cells. This is considered the gold standard for antibody validation .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide before application to verify signal specificity .

• Cross-reactivity testing: Test the antibody on multiple cell lines with known SLK expression levels. The DepMap transcriptomics database can identify suitable cell lines expressing SLK above 2.5 log2 (TPM+1) .

• Multiple antibody concordance: Compare results from different antibodies targeting distinct epitopes of SLK.

• Molecular weight verification: Confirm that detected bands match expected molecular weights (143-160 kDa and/or 210-220 kDa) .

What are effective protocols for SLK colocalization studies in kidney tissue?

For reliable SLK colocalization studies in kidney tissue, follow this protocol adapted from published research:

• Sample preparation: Prepare kidney sections using standard fixation and sectioning techniques.

• Double immunofluorescence staining:

  • For podocyte colocalization: Incubate with rabbit anti-SLK plus rhodamine-goat anti-rabbit and goat anti-synaptopodin plus FITC-rabbit anti-goat

  • For endothelial colocalization: Use rabbit anti-SLK plus FITC-goat anti-rabbit and rat anti-PECAM plus rhodamine-mouse anti-rat

  • For mesangial colocalization: Apply rabbit anti-SLK plus FITC-goat anti-rabbit and mouse anti-Thy1.1 plus Dylight 549-rat anti-mouse

• Quantitative analysis: Measure colocalization using Pearson correlation coefficient with software such as ZEN2010 .

• Controls: Include appropriate single-stained controls to account for bleed-through in fluorescence channels.

This approach has successfully demonstrated that SLK is predominantly expressed in podocytes (Pearson coefficient: 0.27 ± 0.01) with lower expression in endothelial cells (0.07 ± 0.02) and mesangial cells (0.13 ± 0.03) .

What strategies should be employed when using SLK antibodies for immunoprecipitation?

For successful immunoprecipitation of SLK:

• Cell lysis optimization:

  • Use lysis buffer that preserves protein-protein interactions

  • For full-length SLK (~220 kDa), ensure complete extraction with appropriate detergent concentration

• Antibody selection:

  • Choose antibodies specifically validated for IP (e.g., Cell Signaling #41255 at 1:50 dilution)

  • Consider the epitope location - N-terminal vs. C-terminal can affect interaction detection

• Precipitation protocol:

  • Pre-clear lysates to reduce non-specific binding

  • Use appropriate antibody-to-protein ratio (typically 1-5 μg antibody per 500 μg total protein)

  • Incubate overnight at 4°C for optimal binding

• Controls:

  • Include IgG control from the same species as the SLK antibody

  • Use SLK knockout/knockdown samples as negative controls

  • For co-IP studies, verify interaction bidirectionally when possible

• Detection considerations:

  • Use 4-8% SDS-PAGE gels for resolving the high molecular weight SLK protein

  • Consider using gradient gels for simultaneous visualization of SLK and lower molecular weight interacting partners

How can SLK antibodies be effectively used to study its role in cytoskeletal dynamics?

SLK regulates cytoskeletal remodeling, and studying this function requires specialized techniques:

• Stress fiber visualization:

  • Perform double immunofluorescence with SLK antibody (1:50-1:500) and phalloidin to stain F-actin

  • Quantify F-actin stress fiber density and orientation in control versus SLK-depleted cells

• Focal adhesion turnover analysis:

  • Use SLK antibodies in conjunction with paxillin staining

  • Implement live-cell imaging with fluorescently tagged paxillin to measure focal adhesion assembly/disassembly rates after SLK manipulation

  • Quantify focal adhesion size, number, and distribution

• Downstream signaling investigation:

  • Evaluate ezrin expression and phosphorylation, which are decreased in SLK-knockout models

  • Combine with phospho-specific antibodies to examine SLK-mediated phosphorylation events

• Functional assays:

  • Cell adhesion assays (SLK depletion enhances adhesion to collagen-coated substrata by ~35%)

  • Wound-healing migration assays (SLK knockdown reduces cell motility)

  • Assess microvillous transformation and plasma membrane vesiculation as indicators of cytoskeletal disruption

Research has shown that in podocyte-specific SLK-knockout mice, glomerular F-actin is increased, suggesting SLK's regulatory role in actin cytoskeleton homeostasis .

What are the best practices for using SLK antibodies to investigate phosphorylation events?

SLK undergoes autophosphorylation at T183 as part of its activation mechanism. To effectively study SLK phosphorylation:

• Antibody selection:

  • Use phospho-specific antibodies targeting known SLK phosphorylation sites (T183)

  • Confirm specificity using phosphatase treatment as a negative control

• Sample preparation:

  • Rapid cell lysis in the presence of phosphatase inhibitors is crucial

  • Consider using phospho-protein enrichment techniques for low-abundance phosphorylated forms

• Detection methods:

  • Western blotting with phospho-specific antibodies

  • Phos-tag SDS-PAGE for enhanced separation of phosphorylated proteins

  • Immunoprecipitation followed by phospho-specific Western blotting for increased sensitivity

• Kinase activity assays:

  • In vitro kinase assays using immunoprecipitated SLK

  • Analysis of downstream substrate phosphorylation as readout of SLK activity

Research on podocyte-specific SLK-knockout mice demonstrated reduced autophosphorylation of T183, confirming its importance in SLK activation in vivo .

What considerations are important when using SLK antibodies in knockout/knockdown validation studies?

For rigorous validation experiments with SLK antibodies:

• Knockout model selection:

  • Cell lines: HAP1 cells have been successfully used for SLK knockout studies

  • Tissue-specific knockouts: Podocyte-specific SLK deletion using Cre/lox technology provides insight into tissue-specific functions

• Validation approach:

  • Use multiple antibodies targeting different epitopes

  • Employ multiple detection methods (WB, IF, IHC) to confirm knockout

  • Include heterozygous models as additional controls

• Western blot considerations:

  • Load adequate protein (30 μg recommended) for both wild-type and knockout samples

  • Use 4-8% SDS-PAGE gels for proper resolution of the high molecular weight SLK protein

  • Include loading controls that are not affected by SLK deletion

• Functional validation:

  • Complement antibody-based detection with functional assays

  • In SLK knockouts, look for phenotypic changes such as altered cell adhesion, migration, or cytoskeletal organization

  • Check for compensatory upregulation of related kinases

The quality of knockout validation can be assessed by signal-to-noise ratio in Western blots, with complete absence of bands at the expected molecular weights in knockout samples confirming antibody specificity .

How can I distinguish between different functional domains of SLK using domain-specific antibodies?

SLK contains distinct functional domains that can be studied using domain-specific approaches:

• Domain structure and targeting:

  • N-terminal kinase domain (amino acids 1-373)

  • Coiled-coil regions (N-terminal coil: 826-929; C-terminal coil: 942-1038)

  • Consider generating or obtaining antibodies specific to these domains

• Experimental approaches:

  • Use GFP-tagged domain constructs as positive controls for domain-specific antibodies

  • Perform epitope mapping to determine the precise binding region of each antibody

  • Consider using recombinant domain proteins for antibody validation

• Functional analysis:

  • Different domains mediate distinct functions (kinase activity vs. protein-protein interactions)

  • Domain-specific antibodies can be used to block specific functions without affecting others

  • Correlate domain expression with functional outcomes in cell-based assays

• Technical considerations:

  • Some commercial antibodies are raised against specific domains (check the immunogen information)

  • Consider detecting both full-length SLK (210-220 kDa) and potential domain-specific fragments

Research has utilized domain-specific constructs (e.g., SLK 1-373) for studying SLK function, which can serve as controls for domain-specific antibody validation .

Why might I detect multiple bands or different molecular weights when using SLK antibodies in Western blot?

Multiple bands in SLK Western blots can result from several factors:

• Known SLK forms:

  • Full-length SLK (~210-220 kDa)

  • Shorter form (143-160 kDa)

  • Both forms are legitimate and have been observed in multiple studies

• Post-translational modifications:

  • Phosphorylation can cause mobility shifts

  • Other modifications may affect migration patterns

• Proteolytic processing:

  • SLK can undergo cleavage during apoptosis or cell stress

  • Sample preparation methods can influence degradation

• Technical factors:

  • Incomplete protein denaturation of this large protein

  • Inadequate gel separation (use 4-8% gels for high molecular weight proteins)

  • Poor transfer efficiency of large proteins (optimize transfer conditions)

• Validation strategies:

  • Use knockout/knockdown controls to identify specific bands

  • Perform peptide competition assays

  • Compare multiple antibodies targeting different epitopes

What controls are essential when performing immunofluorescence studies with SLK antibodies?

For reliable immunofluorescence results with SLK antibodies:

• Negative controls:

  • SLK knockout/knockdown cells or tissues

  • Primary antibody omission control

  • Isotype control antibody substitution

  • Peptide competition control (pre-incubate antibody with immunizing peptide)

• Positive controls:

  • Cell types with known high SLK expression (e.g., HepG2, H1299 cells)

  • Overexpression systems with tagged SLK

• Specificity controls:

  • Use multiple antibodies targeting different epitopes

  • Correlate staining pattern with known subcellular localization

  • Perform parallel Western blot to confirm antibody specificity

• Quantitative controls:

  • Include standardized exposure settings across samples

  • Use identical image acquisition parameters

  • Implement appropriate colocalization controls when performing double-labeling

• Technical considerations:

  • Optimal fixation method (4% paraformaldehyde recommended)

  • Proper antigen retrieval if needed

  • Appropriate antibody dilution (1:50-1:500 range typically effective)

How should I optimize antibody dilution and incubation conditions for SLK detection in different applications?

Optimization strategies vary by application:

• Western blotting:

  • Start with manufacturer's recommended range (typically 1:500-1:3000)

  • Perform titration experiments with dilutions at 2-fold intervals

  • Optimize primary antibody incubation (overnight at 4°C often yields best results)

  • Consider blocking optimization (5% BSA is often effective)

  • For the large SLK protein, extended transfer times may be necessary

• Immunofluorescence/ICC:

  • Start with 1:50-1:500 dilution range

  • Test different fixation methods (4% paraformaldehyde standard)

  • Optimize permeabilization (0.1-0.5% Triton X-100)

  • Evaluate different blocking solutions (5-10% normal serum)

  • Consider antigen retrieval methods if signal is weak

• Immunoprecipitation:

  • Begin with 1:50 dilution or 1-5 μg of antibody per 500 μg total protein

  • Optimize antibody-to-bead ratio

  • Test different incubation times (4-16 hours at 4°C)

  • Consider pre-clearing lysates to reduce background

• General considerations:

  • Always include both positive and negative controls

  • Document optimized conditions for reproducibility

  • Consider batch-testing antibodies when purchasing new lots

How can SLK antibodies be utilized to study kidney disease mechanisms?

SLK plays a critical role in podocyte function, making it relevant for kidney disease research:

• Podocyte-specific studies:

  • Use anti-SLK antibodies in combination with podocyte markers (synaptopodin, nephrin, podocalyxin)

  • Monitor SLK expression changes during disease progression

  • Evaluate SLK activity through T183 phosphorylation status

• Disease model applications:

  • Podocyte-specific SLK-knockout mice develop progressive albuminuria (starting at 4-5 months in males, 8-9 months in females)

  • Knockout mice show podocyte loss (reduced WT1-positive cells), foot process effacement, and GBM thickening

  • These models can be used to study progression of chronic kidney disease

• Molecular mechanism investigation:

  • SLK deletion reduces nephrin, synaptopodin, and podocalyxin expression

  • Increases glomerular F-actin, suggesting cytoskeletal dysregulation

  • Antibodies can track these molecular changes in disease models

• Quantitative approaches:

  • Use immunofluorescence quantification to measure protein expression changes

  • Electron microscopy with immunogold labeling for ultrastructural localization

  • Western blotting to assess protein level changes during disease progression

Researchers have found that SLK deletion in podocytes leads to microvillous transformation and vesiculation of plasma membranes, indicating its importance in maintaining podocyte structural integrity .

What methodological approaches can be used to investigate SLK's role in cell adhesion and migration?

SLK regulates both cell adhesion and migration, key processes in development and disease:

• Adhesion assays:

  • SLK depletion enhances cell adhesion to collagen-coated substrata (~35% increase)

  • Use static adhesion assays with SLK antibody staining to correlate protein localization with adhesion sites

  • Implement live-cell imaging with fluorescently-tagged SLK to monitor dynamic changes during adhesion

• Migration studies:

  • Wound-healing assays show SLK knockdown reduces cell motility

  • Use time-lapse microscopy with SLK immunofluorescence to track protein redistribution during migration

  • Correlate SLK activity (phospho-SLK) with migration rates

• Molecular mechanistic investigations:

  • Study SLK-mediated phosphorylation of focal adhesion proteins (e.g., paxillin)

  • Examine interaction with cytoskeletal regulators using co-immunoprecipitation

  • Assess changes in Rho GTPase activity following SLK manipulation

• Advanced techniques:

  • FRAP (Fluorescence Recovery After Photobleaching) to study SLK dynamics at adhesion sites

  • Traction force microscopy to measure mechanical forces affected by SLK activity

  • Super-resolution microscopy for detailed localization at adhesion complexes

These approaches can be particularly valuable for understanding SLK's role in cancer cell invasion and metastasis, as well as wound healing processes .

How do researchers effectively use SLK antibodies for comparative studies across species?

When conducting cross-species SLK research:

• Antibody selection considerations:

  • Verify species reactivity (many antibodies are reactive with human and mouse SLK)

  • Check epitope conservation across species of interest

  • Consider using antibodies raised against highly conserved regions for cross-species studies

• Validation requirements:

  • Perform species-specific validation for each application

  • Include appropriate positive controls from each species

  • Consider epitope sequence alignment analysis to predict cross-reactivity

• Technical adjustments:

  • Optimize antibody concentration separately for each species

  • Modify blocking conditions to minimize background in different species

  • Consider species-specific secondary antibodies to reduce cross-reactivity

• Data interpretation:

  • Account for species differences in SLK expression levels and patterns

  • Note differences in protein size or post-translational modifications between species

  • Consider evolutionary conservation of SLK domains when interpreting functional studies

Several commercial antibodies have been validated for both human and mouse SLK detection, facilitating comparative studies between these species . This is particularly valuable for translational research linking mouse models to human disease conditions.